Read on Twitter
Been watching this one. Done a good bit of DD. I’m not in it yet, but might have to make a move on it.
The implication below is $OPK Covid testing play. Severely Undervalued as not everyone knows it’s part of the larger testing infrastructure behind BioReference.
https://twitter.com/jimcramer/status/1295340727807946757
The implication below is $OPK Covid testing play. Severely Undervalued as not everyone knows it’s part of the larger testing infrastructure behind BioReference.
https://twitter.com/jimcramer/status/1295340727807946757
Bio-Reference (ergo $OPK) has the NBA contract. They are the ONLY lab inside the bubble.
They recently started pool testing saliva samples to try and speed process.
In parallel, NBA & Yale were working to validate saliva testing VS. nasal swab testing.
They recently started pool testing saliva samples to try and speed process.
In parallel, NBA & Yale were working to validate saliva testing VS. nasal swab testing.
Yale receives FDA approval for saliva testing on Saturday. 
Yale has the test, Bio-Reference (ergo $OPK) is processing the tests.
Turnaround time drops from 2 DAYS to a few HOURS.
Yale has the test, Bio-Reference (ergo $OPK) is processing the tests.
Turnaround time drops from 2 DAYS to a few HOURS.
Further refining the Yale test is going to allow testing to SCALE. Millions of tests per day. It’s the panacea.
UNLOCKS:
Can handle TSA testing at airport.
Can test entire campuses in few hours.
Massive opp. $OPK is 1st mover here.
Don’t mine the gold. Sell the shovels.
UNLOCKS:
Can handle TSA testing at airport. Can test entire campuses in few hours. Massive opp. $OPK is 1st mover here.
Don’t mine the gold. Sell the shovels.
$OPK Rayaldee is already FDA approved for vitamin D deficiency for stage 3 and 4 renal disease.
Ph 2 study for use in COVID is kicking off next two weeks.
OPK indicating they expect fast track approval once study is completed in mid Sept.
Ph 2 study for use in COVID is kicking off next two weeks.
OPK indicating they expect fast track approval once study is completed in mid Sept.
And $OPK is filing for NDA on stage 5 renal patients (those on dialysis) shortly
And $PFE is filing NDA for HGH in children (partnered with OPK) in Sept which triggers $270M milestone pymt
And OPK guided $380M in q3 ($300M in Q2)
And 140M sh short vs 403M float. Death Trap.
And $PFE is filing NDA for HGH in children (partnered with OPK) in Sept which triggers $270M milestone pymt
And OPK guided $380M in q3 ($300M in Q2)
And 140M sh short vs 403M float. Death Trap.
.... and the $OPK CEO and Founder owns 400m shares. (NOT A TYPO).
-640m sh Out
-403m sh “Float”
-414m sh CEO
140m sh Short (spiked)
DEATH TRAP for Short
’s
-640m sh Out
-403m sh “Float”
-414m sh CEO
140m sh Short (spiked)DEATH TRAP for Short
’s
